Key Highlights

● The Phase 2 study enrolled 92 postmenopausal women, 46 in each arm.

● Daily hot flashes fell by 8.8 events with ABCL635 versus 3.5 with placebo.

● Both primary endpoints were reported as statistically significant.

● Cash and marketable securities totalled $540.1 million at June 30, 2026.

AbCellera Biologics Inc. (NASDAQ:ABCL), an antibody discovery company whose common shares trade on the Nasdaq under the ticker ABCL, announced top-line Phase 2 results for its lead internal programme, ABCL635, on 10 August 2026. The candidate is an antibody that blocks the NK3 receptor and is being studied for moderate-to-severe vasomotor symptoms, the hot flashes associated with menopause.

The randomised, double-blind, placebo-controlled study enrolled 92 postmenopausal women, 46 in each arm, who averaged about ten moderate or severe hot flashes a day. Participants received a single 600 mg subcutaneous injection of ABCL635 or placebo. At week four, daily frequency fell by 8.8 events with ABCL635 against 3.5 with placebo, equivalent to reductions of 83 per cent and 33 per cent. Severity scores dropped by 1.4 points versus 0.3 points, or 58 per cent against 12 per cent. Both primary endpoints were reported as statistically significant (p<0.001).

Safety and the Limits of the Dataset

AbCellera reported no serious adverse events, no severe adverse events and no discontinuations because of adverse events. Headache, fatigue and injection-site reactions were the most common events occurring more often than with placebo. The company also said sleep and patient-reported global impression of change improved, but the release gave no figures for those measures.

The study is small, covers a single dose and measures outcomes at four weeks. The company itself notes that the findings need confirmation in Phase 3, and it did not give a start date or design for later trials. Placebo responses in hot-flash studies can be sizeable, which is why the placebo-adjusted gap of about 50 percentage points in frequency is the more relevant figure than the headline 83 per cent when judging the true treatment effect.

Financial Position at the End of the Second Quarter

The readout followed second-quarter results issued on 5 August 2026. Revenue for the three months ended 30 June 2026 was $4.1 million, compared with $17.1 million a year earlier, with research fees of $3.9 million. The net loss was $55.4 million, or $0.18 per share, compared with $34.7 million in the same quarter of 2025. Research and development spending was $46.0 million, while selling, general and administrative costs fell to $13.9 million from $22.0 million.

Cash was $120.1 million and marketable securities were $420.0 million, a combined $540.1 million on the balance sheet. The press release describes over $565 million in cash and securities and over $675 million of total liquidity including government funding, which is higher than the $540.1 million balance-sheet total.

Partnerships and the Pipeline

Business development continued. A Jazz Pharmaceuticals (NASDAQ:JAZZ) agreement on T-cell engagers for gastrointestinal and other solid tumours carries $84 million of total upfront payments and potential milestones of up to $792 million per programme. On 29 July 2026, AbCellera announced a Vertex Pharmaceuticals (NASDAQ:VRTX) collaboration on multispecific T-cell engagers, with $28 million in total upfront payments. Partner-led programmes in which AbCellera holds a downstream stake numbered 35 at 30 June 2026, down from 44 at the end of 2025.

A Clean Early Signal Still Needs a Phase 3 to Confirm It

A clean early signal gives AbCellera evidence that its internal discovery engine can produce differentiated candidates rather than relying solely on partners. Any wider case for an antibody in this field would rest on dosing convenience and tolerability, which only larger trials can establish.

The company has disclosed no formal financial guidance. Phase 1 dosing for a second candidate, ABCL575, is complete, and top-line data are expected in the fourth quarter of 2026.